Avita Medical
Market Cap
AU$1.7b
Last Updated
2020/02/18 10:32 UTC
Data Sources
Company Financials +
Executive Summary
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Share Price & News
How has Avita Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.2%
AVH
1.5%
AU Biotechs
0.8%
AU Market
1 Year Return
482.1%
AVH
80.7%
AU Biotechs
15.3%
AU Market
Return vs Industry: AVH exceeded the Australian Biotechs industry which returned 78.8% over the past year.
Return vs Market: AVH exceeded the Australian Market which returned 15.6% over the past year.
Shareholder returns
| AVH | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.2% | 1.5% | 0.8% |
| 30 Day | 9.4% | 9.8% | 0.3% |
| 90 Day | 49.5% | 22.1% | 5.3% |
| 1 Year | 482.1%482.1% | 82.8%80.7% | 20.5%15.3% |
| 3 Year | 730.0%640.9% | 183.6%173.4% | 37.4%18.8% |
| 5 Year | 1084.0%944.9% | 264.3%240.6% | 50.7%16.8% |
Price Volatility Vs. Market
How volatile is Avita Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Avita Medical (ASX:AVH) Shareholders Have Enjoyed A Whopping 730% Share Price Gain1 month ago | Simply Wall St
Is Avita Medical Limited (ASX:AVH) Excessively Paying Its CEO?2 months ago | Simply Wall St
Can We See Significant Institutional Ownership On The Avita Medical Limited (ASX:AVH) Share Register?Valuation
Is Avita Medical undervalued compared to its fair value and its price relative to the market?
51.2x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AVH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVH is overvalued based on its PB Ratio (51.2x) compared to the AU Biotechs industry average (2.7x).
Next Steps
Future Growth
How is Avita Medical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
50.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVH's revenue (47.2% per year) is forecast to grow faster than the Australian market (4.3% per year).
High Growth Revenue: AVH's revenue (47.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVH is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Avita Medical performed over the past 5 years?
-34.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVH is currently unprofitable.
Growing Profit Margin: AVH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVH is unprofitable, and losses have increased over the past 5 years at a rate of -34.7% per year.
Accelerating Growth: Unable to compare AVH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7%).
Return on Equity
High ROE: AVH has a negative Return on Equity (-118.03%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Avita Medical's financial position?
Financial Position Analysis
Short Term Liabilities: AVH's short term assets (A$34.6M) exceed its short term liabilities (A$6.3M).
Long Term Liabilities: AVH's short term assets (A$34.6M) exceed its long term liabilities (A$664.7K).
Debt to Equity History and Analysis
Debt Level: AVH is debt free.
Reducing Debt: AVH has not had any debt for past 5 years.
Balance Sheet
Inventory Level: AVH has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AVH's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AVH has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.1% each year
Next Steps
Dividend
What is Avita Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AVH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AVH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.9yrs
Average management tenure
CEO
Mike Perry (60yo)
2.7yrs
Tenure
AU$2,384,877
Compensation
Dr. Michael S. Perry, also known as Mike, DVM, Ph.D., FACVPT, is a Director at Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.) since 2019. He has been Chief Executive Officer of Avita Medica ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD1.60M) is above average for companies of similar size in the Australian market ($USD931.92K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.7yrs | AU$2.38m | 0.60% A$10.4m | |
| Chief Technology Officer | 0.8yrs | AU$765.89k | no data | |
| Chief Administrative Officer | 2.2yrs | AU$765.88k | no data | |
| General Counsel | 1.7yrs | AU$807.83k | no data | |
| Chief Commercial Officer | 2.5yrs | AU$817.77k | no data | |
| Chief Financial Officer | 0.3yrs | no data | no data | |
| Vice President of Global Operations | 4.3yrs | no data | no data | |
| Vice President of Global Marketing | 1.6yrs | no data | no data | |
| Company Secretary | 1.9yrs | no data | no data |
1.9yrs
Average Tenure
51yo
Average Age
Experienced Management: AVH's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.7yrs | AU$2.38m | 0.60% A$10.4m | |
| Independent Non-Executive Director | 7.3yrs | AU$61.04k | no data | |
| Independent Non-Executive Director | 4.1yrs | AU$60.81k | 0.0016% A$27.6k | |
| Founder and Member of Clinical Advisory Board | 4.1yrs | AU$40.00k | no data | |
| Independent Non-Executive Chairman | 5.6yrs | AU$86.23k | 0.094% A$1.6m | |
| Independent Non-Executive Director | 4.1yrs | AU$61.04k | 0.014% A$243.2k | |
| Independent Non-Executive Director | 4.1yrs | AU$61.13k | 0.075% A$1.3m |
4.1yrs
Average Tenure
65yo
Average Age
Experienced Board: AVH's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.6%.
Top Shareholders
Company Information
Avita Medical Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Avita Medical Limited
- Ticker: AVH
- Exchange: ASX
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.726b
- Shares outstanding: 2.12b
- Website: https://www.avitamedical.com
Number of Employees
Location
- Avita Medical Limited
- 28159 Avenue Stanford
- Suite 220
- Valencia
- California
- 91355
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AVMX.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 1999 |
| GCR | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 1999 |
| AVH | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jul 1999 |
| AVH | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jul 1999 |
| RCEL | NasdaqCM (Nasdaq Capital Market) | SPONSORED ADS | US | USD | Mar 2012 |
Biography
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company has a preclinical research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa. The company is based in Valencia, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/18 10:32 |
| End of Day Share Price | 2020/02/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.